371 related articles for article (PubMed ID: 37272727)
1. Immunotherapy in leukaemia.
Mu X; Chen C; Dong L; Kang Z; Sun Z; Chen X; Zheng J; Zhang Y
Acta Biochim Biophys Sin (Shanghai); 2023 Jun; 55(6):974-987. PubMed ID: 37272727
[TBL] [Abstract][Full Text] [Related]
2. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukaemia and the immune system: implications for immunotherapy.
Barrett AJ
Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805
[TBL] [Abstract][Full Text] [Related]
4. Immune-Based Therapies in Acute Leukemia.
Witkowski MT; Lasry A; Carroll WL; Aifantis I
Trends Cancer; 2019 Oct; 5(10):604-618. PubMed ID: 31706508
[TBL] [Abstract][Full Text] [Related]
5. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia.
Casirati G; Cosentino A; Mucci A; Salah Mahmoud M; Ugarte Zabala I; Zeng J; Ficarro SB; Klatt D; Brendel C; Rambaldi A; Ritz J; Marto JA; Pellin D; Bauer DE; Armstrong SA; Genovese P
Nature; 2023 Sep; 621(7978):404-414. PubMed ID: 37648862
[TBL] [Abstract][Full Text] [Related]
6. The progress and current status of immunotherapy in acute myeloid leukemia.
Yang D; Zhang X; Zhang X; Xu Y
Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy prospects for acute myeloid leukaemia.
Barrett AJ; Le Blanc K
Clin Exp Immunol; 2010 Aug; 161(2):223-32. PubMed ID: 20529084
[TBL] [Abstract][Full Text] [Related]
8. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.
Cheuk AT; Guinn BA
Front Biosci; 2008 Jan; 13():2022-9. PubMed ID: 17981688
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting.
Han L; Xing H; Cao W; Song Y; Jiang Z; Yu J
Expert Opin Biol Ther; 2024 Apr; 24(4):221-223. PubMed ID: 38506624
[TBL] [Abstract][Full Text] [Related]
11. Catch me if you can: how AML and its niche escape immunotherapy.
Tettamanti S; Pievani A; Biondi A; Dotti G; Serafini M
Leukemia; 2022 Jan; 36(1):13-22. PubMed ID: 34302116
[TBL] [Abstract][Full Text] [Related]
12. Immune escape and immunotherapy of acute myeloid leukemia.
Vago L; Gojo I
J Clin Invest; 2020 Apr; 130(4):1552-1564. PubMed ID: 32235097
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.
Smits EL; Lee C; Hardwick N; Brooks S; Van Tendeloo VF; Orchard K; Guinn BA
Cancer Immunol Immunother; 2011 Jun; 60(6):757-69. PubMed ID: 21519825
[TBL] [Abstract][Full Text] [Related]
14. [Acute lymphoblastic leukaemia as a secondary malignoma after treatment of acute myeloic leukaemia (AML/M4)].
Hasanbegović E
Med Arh; 2006; 60(5):315-6. PubMed ID: 16944736
[TBL] [Abstract][Full Text] [Related]
15. Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.
Foa R; Meloni G; Tosti S; Novarino A; Fenu S; Guarini A; Cardona S; Gillio Tos A; Gavosto F; Mandelli F
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():98-102. PubMed ID: 2202476
[No Abstract] [Full Text] [Related]
16. Immunotherapies in acute leukemia.
Boissel N; Rabian F
Therapie; 2022; 77(2):241-250. PubMed ID: 34924207
[TBL] [Abstract][Full Text] [Related]
17. Role of CXCR4 in the progression and therapy of acute leukaemia.
Su L; Hu Z; Yang YG
Cell Prolif; 2021 Jul; 54(7):e13076. PubMed ID: 34050566
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.
Barsan V; Ramakrishna S; Davis KL
Curr Oncol Rep; 2020 Jan; 22(2):11. PubMed ID: 31997022
[TBL] [Abstract][Full Text] [Related]
19. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intracellular immune checkpoint-silenced DC vaccine.
Wang D; Huang XF; Hong B; Song XT; Hu L; Jiang M; Zhang B; Ning H; Li Y; Xu C; Lou X; Li B; Yu Z; Hu J; Chen J; Yang F; Gao H; Ding G; Liao L; Rollins L; Jones L; Chen SY; Chen H
JCI Insight; 2018 Feb; 3(3):. PubMed ID: 29415891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
